|
|
||||||||||||||
|
|
|||||||||||||||
Reviews |
Department of Neurosciences, University of California, San Diego, San Diego Veterans Affairs Medical Center, La Jolla, CA, USA
Correspondence to:
Correspondence to:
J Corey-Bloom, MD, PhD, Neurology Service (9127), San Diego VA Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161-3064, USA;
jcoreybl@vapop.ucsd.edu
| The first 150 words of the full text of this article appear below. |
|
Alzheimers disease is a degenerative brain disorder characterised by progressive dementia that culminates in death. It affects 3% of those over the age of 65 and up to 50% over the age of 85, resulting in a cost of over $100 billion a year in the USA.1 Due to the ageing population, the societal burden of this disease is expected to increase over the next 40 years.2 The hallmark of Alzheimers disease is the insidious onset of memory loss, although one or more additional areas of cognitive impairment are usually evident on examination. Slow but relentless progression leads to worsening cognitive and behavioural problems, as the result of widespread areas of cortical dysfunction. Effective management consists of both pharmacological and non-pharmacological interventions to improve the quality of life of patientsand their carers.
PHARMACOLOGICAL TREATMENT
Current pharmacological treatments include both disease specific compounds as well as adjunctive therapies for the behavioural symptoms of
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |